NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, Price Target & More

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) issued its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.19. The biotechnology company earned $4.85 million during the quarter, compared to the consensus estimate of $15.63 million. Momenta Pharmaceuticals had a negative return on equity of 28.56% and a negative net margin of 88.77%. Momenta Pharmaceuticals's quarterly revenue was down 81.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.46) EPS. View Momenta Pharmaceuticals' Earnings History.

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Momenta Pharmaceuticals.

8 analysts have issued 1-year price targets for Momenta Pharmaceuticals' shares. Their forecasts range from $6.00 to $24.00. On average, they expect Momenta Pharmaceuticals' stock price to reach $15.6250 in the next twelve months. View Analyst Ratings for Momenta Pharmaceuticals.

Some companies that are related to Momenta Pharmaceuticals include BIO-TECHNE (TECH), Ablynx (ABLYF), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Repligen (RGEN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Acceleron Pharma (XLRN) and Denali Therapeutics (DNLI).

Media stories about MNTA stock have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 0.22 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.38 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Momenta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.89%), Palo Alto Investors LP (2.36%), Fiera Capital Corp (1.41%), Dimensional Fund Advisors LP (1.32%), Northern Trust Corp (1.19%) and JPMorgan Chase & Co. (0.88%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, Richard P Shea, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.

MNTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Fiera Capital Corp, Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., Oppenheimer Asset Management Inc., American International Group Inc. and Wells Fargo & Company MN. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Scott M Storer and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.

MNTA stock was purchased by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Eventide Asset Management LLC, Rock Springs Capital Management LP, BlackRock Inc., UBS Group AG, American Century Companies Inc., Mackay Shields LLC and Prudential Financial Inc.. View Insider Buying and Selling for Momenta Pharmaceuticals.

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MNTA stock can currently be purchased for approximately $21.45.

Momenta Pharmaceuticals has a market capitalization of $1.73 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]